Cheshire and Merseyside

UPADACITINIB prolonged-release tablets (RINVOQ® ▼) for Crohn's disease

The Cheshire and Merseyside Area Prescribing Group recommends the prescribing of UPADACITINIB prolonged-release tablets (RINVOQ® ▼), by specialists only, for previously treated moderately to severely active Crohn's disease in accordance with NICE TA905.

RED

NICE technology appraisal TA905 (21 June 2023) recommends upadacitinib as an option for treating moderately to severely active Crohn's disease in adults, only if:

- the disease has not responded well enough or lost response to a previous biological treatment **or**
- a previous biological treatment was not tolerated **or**
- tumour necrosis factor (TNF)-alpha inhibitors are contraindicated **and**
- the company provides it according to the commercial arrangement.[1]

If people with the condition and their clinicians consider upadacitinib to be one of a range of suitable treatments, after discussing the advantages and disadvantages of all options, the least expensive should be chosen taking into account administration costs, dosage, price per dose and commercial arrangements.[1]

Prescribing and monitoring should be retained by a specialist in the treatment of Crohn's disease.

Costing information

Modelling within the NICE resource impact template estimates that implementing TA905 will likely be cost-neutral, with the potential for a cost-saving, based on the NHS list price.

References

1. National Institute for Health and Care Excellence. Technology Appraisal 905; Upadacitinib for previously treated moderately to severely active Crohn's disease, 21 June 2023. Accessed 22 June 2023

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.